Morgan Stanley analyst Erin Wright raised the firm’s price target on Quest Diagnostics (DGX) to $191 from $182 and keeps an Overweight rating on the shares following a “clean beat and raise” report. Quest raised its 2025 EPS guidance to $9.63-$9.83 and projects the favorable environment should now support 9.4%-10.6% revenue growth in 2025 as strong utilization persists, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $180 from $175 at UBS
- Quest Diagnostics price target raised to $192 from $190 at Truist
- Quest Diagnostics price target raised to $178 from $160 at Deutsche Bank
- Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating
- Quest Diagnostics: Strong Performance and Growth Potential Justify Buy Rating